There are anecdotal responses to single-agent BV in patients with T-cell PTLD, suggesting that BV can be effective in CD30-expressing T-cell lymphomas arising in immunocompromised patients [6,8]. This evidence concerns the gene TNFRSF8 and T-cell non-Hodgkin lymphoma.